Upadacitinib ER is under clinical development by AbbVie and currently in Pre-Registration for Crohn’s Disease (Regional Enteritis). According to GlobalData, Pre-Registration drugs for Crohn’s Disease (Regional Enteritis) have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Upadacitinib ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Upadacitinib ER overview
Upadacitinib (Rinvoq, Rim-Voq, Refu) is an antineoplastic drug, acts as immunosuppressive agent. It is formulated as extended release tablets, extended release coated tablets and extended release film coated tablets for oral route of administration. Rinvoq is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate and is indicated as monotherapy or in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs), indicated for active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs and also indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. Rinvoq is indicated for the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe atopic dermatitis (AD) who are not adequately controlled with a systemic treatment (e.g., steroid or biologic) or when use of those therapies is inadvisable. Rinvoq is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. Rinvoq is indicated for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. Rinvoq is indicated for the treatment of ankylosing spondylitis, which is inadequately effective with existing treatments in adults. Rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation, as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Upadacitinib tartrate (ABT-494) is under development for the treatment of alopecia, non-segmental vitiligo, moderate to severe hidradenitis suppurativa, moderately to severely active systemic lupus erythematosus, moderately to severely active rheumatoid arthritis (RA), psoriatic arthritis, Takayasu arteritis, ulcerative colitis, spondyloarthritis, juvenile idiopathic arthritis, oligoarticular idiopathic juvenile arthritis, polyarticular juvenile idiopathic arthritis, Crohn's disease in adults and pediatric patients, giant cell arteritis and ankylosing spondylitis. ABT-494 is administered through oral route as a tablet. The drug candidate targets JAK 1. It was also under development for the treatment of moderate to severe atopic dermatitis.
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
For a complete picture of Upadacitinib ER’s drug-specific PTSR and LoA scores, buy the report here.